Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jes Dietrich

Showing results (31-40 of 58) with videos related to

Pageof 6
Sort By:
NPJ Vaccines|January 30, 2020
Parenteral vaccination protects against transcervical infection with <i>Chlamydia trachomatis</i> and generate tissue-resident T cells post-challengeNina Dieu Nhien Tran Nguyen, Anja W Olsen, Emma Lorenzen, et al.
Immunology|February 17, 2007
The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomesKaren Smith Korsholm, Else Marie Agger, Camilla Foged, et al.
Plos One|June 17, 2009
Distinct differences in the expansion and phenotype of TB10.4 specific CD8 and CD4 T cells after infection with Mycobacterium tuberculosisTruc Thi Kim Thanh Hoang, Anneline Nansen, Sugata Roy, et al.
NPJ Vaccines|April 2, 2025
Post-exposure vaccine protection of CTH522/CAF<sup>®</sup>01 against reinfection with Chlamydia trachomatis requires Th1/Th17 but not Th2-immunityNina Dieu Nhien Tran Nguyen, Sharmila Subratheepam, Safia Guleed, et al.
Nature Communications|February 23, 2024
Immune signature of Chlamydia vaccine CTH522/CAF®01 translates from mouse-to-human and induces durable protection in miceAnja W Olsen, Ida Rosenkrands, Christina S Jacobsen, et al.
Plos One|April 10, 2009
CD4 and CD8 T cell responses to the M. tuberculosis Ag85B-TB10.4 promoted by adjuvanted subunit, adenovector or heterologous prime boost vaccinationTara Elvang, Jan P Christensen, Rolf Billeskov, et al.
Plos One|December 19, 2013
ESAT-6 (EsxA) and TB10.4 (EsxH) based vaccines for pre- and post-exposure tuberculosis vaccinationTruc Hoang, Claus Aagaard, Jes Dietrich, et al.
Traffic (Copenhagen, Denmark)|August 7, 2004
Masking of the CD3 gamma di-leucine-based motif by zeta is required for efficient T-cell receptor expressionJens Peter H Lauritsen, Charlotte Menné Bonefeld, Marina von Essen, et al.
Nature Medicine|January 25, 2011
A multistage tuberculosis vaccine that confers efficient protection before and after exposureClaus Aagaard, Truc Hoang, Jes Dietrich, et al.
Plos One|June 17, 2009
Protection and polyfunctional T cells induced by Ag85B-TB10.4/IC31 against Mycobacterium tuberculosis is highly dependent on the antigen doseClaus Aagaard, Truc Thi Kim Thanh Hoang, Angelo Izzo, et al.
Pageof 6

Showing results (31-40 of 58) with videos related to

Sort By:
Pageof 6
NPJ Vaccines|January 30, 2020
Parenteral vaccination protects against transcervical infection with <i>Chlamydia trachomatis</i> and generate tissue-resident T cells post-challengeNina Dieu Nhien Tran Nguyen, Anja W Olsen, Emma Lorenzen, et al.
Immunology|February 17, 2007
The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomesKaren Smith Korsholm, Else Marie Agger, Camilla Foged, et al.
Plos One|June 17, 2009
Distinct differences in the expansion and phenotype of TB10.4 specific CD8 and CD4 T cells after infection with Mycobacterium tuberculosisTruc Thi Kim Thanh Hoang, Anneline Nansen, Sugata Roy, et al.
NPJ Vaccines|April 2, 2025
Post-exposure vaccine protection of CTH522/CAF<sup>®</sup>01 against reinfection with Chlamydia trachomatis requires Th1/Th17 but not Th2-immunityNina Dieu Nhien Tran Nguyen, Sharmila Subratheepam, Safia Guleed, et al.
Nature Communications|February 23, 2024
Immune signature of Chlamydia vaccine CTH522/CAF®01 translates from mouse-to-human and induces durable protection in miceAnja W Olsen, Ida Rosenkrands, Christina S Jacobsen, et al.
Plos One|April 10, 2009
CD4 and CD8 T cell responses to the M. tuberculosis Ag85B-TB10.4 promoted by adjuvanted subunit, adenovector or heterologous prime boost vaccinationTara Elvang, Jan P Christensen, Rolf Billeskov, et al.
Plos One|December 19, 2013
ESAT-6 (EsxA) and TB10.4 (EsxH) based vaccines for pre- and post-exposure tuberculosis vaccinationTruc Hoang, Claus Aagaard, Jes Dietrich, et al.
Traffic (Copenhagen, Denmark)|August 7, 2004
Masking of the CD3 gamma di-leucine-based motif by zeta is required for efficient T-cell receptor expressionJens Peter H Lauritsen, Charlotte Menné Bonefeld, Marina von Essen, et al.
Nature Medicine|January 25, 2011
A multistage tuberculosis vaccine that confers efficient protection before and after exposureClaus Aagaard, Truc Hoang, Jes Dietrich, et al.
Plos One|June 17, 2009
Protection and polyfunctional T cells induced by Ag85B-TB10.4/IC31 against Mycobacterium tuberculosis is highly dependent on the antigen doseClaus Aagaard, Truc Thi Kim Thanh Hoang, Angelo Izzo, et al.
Pageof 6